Prima BioMed (NASDAQ:IMMP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Prima BioMed (NASDAQ:IMMP) from a sell rating to a hold rating in a report issued on Saturday morning.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Prima BioMed in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Prima BioMed Trading Down 3.6%

Shares of IMMP stock opened at $2.64 on Friday. Prima BioMed has a 52-week low of $1.32 and a 52-week high of $3.53. The business’s fifty day moving average is $2.85 and its 200 day moving average is $2.17.

Institutional Investors Weigh In On Prima BioMed

A hedge fund recently raised its stake in Prima BioMed stock. Jane Street Group LLC grew its position in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent reporting period. 2.32% of the stock is owned by hedge funds and other institutional investors.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.